FDA warns Healthy Male that its website sells compounded tirzepatide with false or misleading 'clinically proven' weight-loss claims.
What happened
FDA reviewed the website https://healthymale.com in August 2025. FDA found the site offering compounded drug products, including tirzepatide, with claims such as “Clinically shown to support 15-22% average body weight reduction” and “Clinically proven” for weight management. FDA says these claims are false or misleading because compounded drugs are not FDA-approved.
What FDA found
FDA says the website's claims for compounded tirzepatide are false or misleading because they suggest the products are the same as FDA-approved drugs.
FDCA §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website uses 'clinically shown' and 'clinically proven' weight-loss claims, but compounded drugs are not FDA-approved.
FDCA §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA says selling these misbranded drugs across state lines is a prohibited act.
FDCA § 301(a) [21 U.S.C. § 331(a)]FDA also notes that receiving misbranded drugs in interstate commerce is prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells Healthy Male to stop using the misleading claims and to send a written response within 15 working days describing corrective steps, how it will prevent recurrence, and supporting documents.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies and their marketing partners
- online sellers making 'clinically proven' weight-loss claims
This is a summary. Read the original letter on fda.gov.